Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® …
2023年12月19日 · FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB) …
Filsuvez
Chiesi Global Rare Diseases is a family-owned and run biopharmaceutical company with a commitment to providing transformative care to patients with rare diseases.
FDA Approves Topical Gel Filsuvez for Epidermolysis Bullosa
2023年12月20日 · Filsuvez will be available for patients to administer in an at-home setting and is administered directly to the wound at each dressing change. Reference. Chiesi Global Rare …
News and Press Releases | Chiesi Global Rare Diseases
BOSTON, December 19, 2023 - Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, …
Our Approved Products | Chiesi Global Rare Diseases
FILSUVEZ may cause a serious side effect of allergic reactions. Allergic reactions and skin reactions to FILSUVEZ may include the following symptoms: red itchy bumps (hives), skin …
Rare Disease Rundown: Rare Disease News From the Past 365 Days
2024年2月29日 · Chiesi Global Rare Diseases. Chiesi Global Rare Diseases receives FDA approval for FILSUVEZ (birch triterpenes) topical gel for the treatment of epidermolysis …
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® …
2024年3月7日 · - Data published in Genetics in Medicine demonstrate continuous benefits up to six years of treatment - BOSTON, March 7, 2024 - Chiesi Global Rare Diseases, a business …
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on …
Epidermolysis Bullosa Market Predicted to Grow in United States …
2023年8月11日 · In the US, the only US Food and Drug Administration (FDA)-approved therapy is beremagene geperpavec (Vyjuvek) made by Krystal Biotech. In the EU, Oleogel-S10 …
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® …
2024年3月1日 · In the Press. News Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community